A 55-year-old marathon runner and a 55-year-old with diabetes, hypertension, and a two-decade smoking history are the same chronological age. Almost no clinician would treat their cardiovascular risk the same way — and yet the tools most risk calculators are built on (SCORE2, the ASCVD Risk Estimator) start from the same input for both of them: age in years since birth.
Chronological age is a convenient proxy for biological wear — the actual, cumulative decline in arteries, immune function, and metabolic regulation that drives atherosclerosis. It's a proxy, not the thing itself. Over the past decade, a different way of estimating that underlying biological state has moved from research cohorts into early clinical use: epigenetic clocks.
Why chronological age falls short
SCORE2 and similar tools work well at a population level — they're guideline-anchored and validated across large cohorts. But within any given age band, cardiovascular trajectories fan out widely. Smoking, diabetes duration, inflammatory burden, and inherited lipid risk (like elevated Lp(a)) all push two people of identical age onto very different curves. Chronological age can't see any of that directly — it only sees the calendar.
Biological aging is the attempt to measure the wear itself, rather than infer it from birth year. Epigenetic clocks — built on patterns of DNA methylation, chemical marks that accumulate on DNA over a lifetime and shift with cellular aging — are currently the most extensively validated way to do that.
Chronological age answers "how many years since you were born." Biological age asks "how much wear has actually accumulated." For cardiovascular risk, the second question is the one that matters — and for most people, nobody has ever measured it directly.
Three clocks, three different jobs
"Epigenetic clock" isn't one test — it's a family of algorithms trained on different targets. For cardiovascular prevention, three are worth knowing apart:
| Clock | What it's trained to predict | What it needs |
|---|---|---|
| GrimAge | Time-to-death and healthspan, via methylation surrogates of plasma proteins (including PAI-1 and GDF-15) plus smoking history | DNA methylation assay |
| DunedinPACE | Current pace of aging — how fast multiple organ systems are declining right now, not a fixed age | DNA methylation assay |
| PhenoAge | A "phenotypic age" built from a composite of routine clinical chemistry (including albumin, creatinine, glucose, CRP, and white-cell indices) plus chronological age | Standard bloodwork — no methylation test |
GrimAge and DunedinPACE come from the same broad family of DNA methylation-based clocks (Lu et al., Aging, 2019; Belsky et al., eLife, 2022), refined from an earlier "phenotypic age" concept (Levine et al., Aging, 2018) that could be estimated from bloodwork alone. That distinction matters more than it looks: it's the difference between a test that needs a specialized methylation assay sent to a dedicated lab, and one that could, in principle, be estimated from labs a patient may already have.
What the cardiovascular evidence actually shows
In the Multi-Ethnic Study of Atherosclerosis, GrimAge acceleration was independently associated with incident composite cardiovascular disease (HR 1.05, 95% CI 1.02–1.08) and stroke (HR 1.08, 95% CI 1.04–1.13), after adjustment for standard risk factors. The association with heart failure was strongest for the mildly-reduced-ejection-fraction subtype specifically (HR 1.31, 95% CI 1.13–1.53). Notably, the link to incident myocardial infarction weakened in participants with a coronary artery calcium (CAC) score of zero, but remained significant in those with CAC >0 (HR 1.09, 95% CI 1.03–1.16) — GrimAge's signal looks most informative once some plaque already exists, not as a stand-alone substitute for CAC in a CAC-zero patient.
Because DunedinPACE is trained to detect change over a matter of years rather than a lifetime, it can move within months of an intervention — where GrimAge typically shifts more slowly. In a 32-week randomized, placebo-controlled trial of semaglutide in adults with HIV-associated lipohypertrophy, the treatment group showed a significantly slower pace of aging on DunedinPACE than placebo (roughly 9% slower, p=0.010) — and GrimAge2 also moved significantly in this particular trial (p=0.009), which is notable given how slowly it usually changes.
Read together, these two studies point in the same direction as the rest of the cardiometabolic evidence base: biological aging is measurable, it correlates with real cardiovascular outcomes, and — at least on DunedinPACE — it appears responsive to the same metabolic interventions (GLP-1 receptor agonists, weight optimization, lifestyle change) already discussed elsewhere in this longevity framework.
Where this fits next to ApoB, Lp(a), and inflammation
Epigenetic clocks don't replace the markers a cardiovascular prevention panel already reads — they sit alongside them, and arguably explain part of why those markers matter as much as they do:
- ApoB and LDL-C capture cumulative atherogenic particle exposure — the driver, not the aging process itself.
- Lp(a) is an inherited, largely fixed risk that doesn't change with lifestyle — a genuinely separate axis from biological aging.
- hs-CRP and metabolic markers (TyG Index, AIP) track residual inflammation and insulin resistance — both are proposed mechanistic contributors to epigenetic age acceleration itself.
A patient with elevated Lp(a) and signs of accelerated biological aging is not necessarily the same risk as a patient with elevated Lp(a) alone — though this specific combination is still an emerging research question, not yet a validated clinical decision rule. It's a reason to take the whole picture to a physician, not a reason to draw conclusions from any single number.
Investigational RNA-targeted therapies for Lp(a) — pelacarsen and olpasiran among them — are in ongoing outcomes trials, with no completed outcome data yet. They are not approved treatments today. See our guide to the Lp(a) drug pipeline for where each trial actually stands.
What CardioIQ measures today — and what this isn't, yet
To be direct about scope: CardioIQ's report interprets routine lipid and cardiometabolic labs — full lipid panel, ApoB, Lp(a), glucose/insulin, hs-CRP, and related markers most people can already order — against longevity-optimal targets. It does not currently include DNA methylation testing, so GrimAge and DunedinPACE are not part of a CardioIQ report today. This article exists because the science is moving there, and because the pillar it belongs to — long-horizon, biological-age-aware prevention — is the frame the rest of a longevity-optimal panel already serves.
In the meantime, the practical takeaway holds up even without a methylation test: the interventions shown so far to slow measured biological aging — GLP-1 receptor agonists where indicated, weight and metabolic optimization, exercise, sleep, and getting ApoB, Lp(a), and inflammatory markers to target — are the same actions a longevity-optimal cardiometabolic reading already points toward. You don't need to wait for a biological-age test to start on the part that's already actionable.
Frequently asked questions
Can I get my epigenetic age tested through CardioIQ today?
Not yet. CardioIQ interprets routine lipid and cardiometabolic labs against longevity-optimal targets. GrimAge and DunedinPACE need a separate DNA methylation assay, which isn't part of the current panel.
Is biological age the same thing as an epigenetic clock?
Epigenetic clocks are the best-validated way to estimate biological age right now, but not the only one. Composite clinical measures like PhenoAge estimate a related concept from routine bloodwork, without a methylation test.
Does a faster epigenetic clock mean I'll have a heart attack?
No. It's a population-level risk marker studied in cohorts like MESA — it shifts probabilities, it doesn't predict an individual outcome. Treat it as a reference-frame data point for a conversation with your physician, not a verdict.
If I can't test this yet, what can I actually do?
Focus on what's already measurable: ApoB, Lp(a), hs-CRP, and metabolic health. The same levers shown to slow biological aging in early trials — metabolic optimization, exercise, sleep, and appropriate pharmacologic therapy — are the ones a longevity-optimal panel already surfaces.
Read your current labs against longevity-optimal targets
CardioIQ interprets your lipid panel, ApoB, and Lp(a) against targets calibrated to your risk category — not just population "normal."
Choose your report → Or try the free Optimal vs Normal check — no sign-up required.References
- Srivatsa S, Rice N, Pike JR, Smith JA, Ding J, Liu Y, Budoff M, Bey GS. Epigenetic Aging Clocks and Incident Cardiovascular Outcomes: Results From the MESA. J Am Heart Assoc. 2025;14(24):e044946. doi:10.1161/JAHA.125.044946
- Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11:e73420. doi:10.7554/eLife.73420
- Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY). 2019;11(2):303–327. doi:10.18632/aging.101684
- Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018;10(4):573–591. doi:10.18632/aging.101414
- Corley MJ, et al. Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy. Nat Commun. 2026;17:6606. doi:10.1038/s41467-026-72861-3